Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Oncogene. 2014 Sep 22;34(29):3770–3779. doi: 10.1038/onc.2014.304

Figure 4. Survivin antagonists alter cell cycle progression and promote apoptosis.

Figure 4

(A-H) Ptch mutant tumor cells were treated with either DMSO (A,B,E,F), 20 μg/ml S12 (C,D), or 100 nM YM155 (G,H) and stained with 7-AAD for cell cycle analysis after 24 hr (A,C,E,G) or 36 hr (B,D,F,H). YM155 decreased the percentage of cells in G2/M, while S12 treatment caused an accumulation of cells in G2/M. Data represent 4 (A-D) and 6 (E-H) experiments and percentages based on live cell gates (excluded subG1). (I-K) Tumor cells were treated with DMSO (I), 20 μg/ml (J), or 100nM YM155 (K) for 36 hr, then collected and stained with Propidium Iodide (PI) and Annexin-V for FACS analysis. The percentage of apoptotic cells was significantly higher after antagonist treatment compared to control. Data represent 6 independent experiments.